EUCTR2007-004335-39-NL进行中（未招募）不适用
A randomized phase II trial of docetaxel plus carboplatin versus docetaxel in hormone refractory prostate cancer patients who have progressed after response to prior docetaxel chemotherapy: RECARDO STUDY - RECARDO
VU Medical Center0 个研究点目标入组 150 人开始时间: 2009年3月13日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1.18 years and above.
- •2.Histologically proven hormone refractory prostate adenocarcinoma.
- •3.PSA and/or clinical response on prior docetaxel-based chemotherapy with a progression free interval of over 3 months.
- •4.Last PSA value = 5 ng/ml within 2 weeks prior to registration (HYBRITECH equivalent)
- •5.Patients without surgical castration must continue on LHRH agonist therapy
- •6.ECOG performance status = 2
- •7.Gleason score 8-10
- •8.Adequate haematological, liver and renal function.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years)
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.More than 1 line of chemotherapy.
- •2.Prior platinum chemotherapy.
- •3.Radiotherapy within 2 weeks prior to treatment start.
- •4.Uncontrolled hypercalcemia.
- •5.Evidence of symptomatic brain and leptomeningeal metastatic disease.
- •6.Previous or concurrent malignancies at other sites (except basal squamous cell carcinoma of the skin).
研究者
相似试验
已完成
2 期
A randomized phase II trial of docetaxel plus carboplatin versus docetaxel in hormone refractory prostate cancer patients who have progressed after response to prior docetaxel chemotherapy: RECARDO STUDYNL-OMON35127Vrije Universiteit Medisch Centrum150
招募中
不适用
Docetaxel met carboplatine versus docetaxel, een gerandomiseerde fase 2 studie bij patiënten met hormoonongevoelig prostaatkanker na eerdere respons op docetaxel-bevattende chemotherapie: RECARDO STUDIE.Hormone refractory prostate cancerNL-OMON27233VU Medisch Centrum150
已完成
2 期
Randomized phase II trial of docetaxel and carboplatin in patients with stage IIIB/IV non-small cell lung cancer.Stage IIIB/IV non-small cell lung cancerJPRN-UMIN000001225The Japan-multinational Trial Organization90
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - DOCOX GASTRIC (Docetaxel-Oxaliplatin in Gastric Cancer)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-HUSanofi-aventis groupe270
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - GATE (GAstric cancer study with Taxotere-Eloxatin-based regimens)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-BESanofi-aventis groupe270